• Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation
• NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics
• Collaboration aligns with Bio-Techne's strategic growth pillars and megatrends in precision medicine

Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.

"This partnership marks an exciting step forward in how we are using artificial intelligence to advance scientific progress," said Will Geist, President of the Protein Sciences Segment at Bio-Techne. "NovoBody™ Duo molecules extend our portfolio with innovative AI-powered designs and state-of-the-art customization, stability, and performance, enabling customers to target complex biology with greater precision and accelerate the development of better therapies."

Alfredo Quijano Rubio, PhD, CSO of Monod Bio commented, "NovoBody™ Duo molecules are compact, tunable, and rapidly adaptable for multi-specific binding applications. Unlike traditional antibodies, they can be engineered quickly and cost-effectively, making them ideal for next-generation research tools and diagnostics."

"We are thrilled to partner with Bio-Techne, whose commitment to innovation and scientific excellence aligns perfectly with our mission," said Daniel Silva Manzano, PhD, CEO of Monod Bio. "This collaboration validates our platform and accelerates the integration of Monod's AI-designed proteins into mainstream life sciences."

The agreement supports Bio-Techne's strategic growth vectors, supporting the discovery of novel biological insights and the development of advanced therapeutics. It also reinforces the company's position at the forefront of AI-enabled innovation—a key megatrend driving global healthcare transformation.